Find Funding Opportunities

The Office of Research on Women's Health (ORWH) and cosponsoring Institutes and Offices (IC) of the National Institutes of Health (NIH) invite submission of investigator-initiated research grant applications to support research on the epidemiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS) in diverse groups and across the life span.

- The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Arthritis and Skin Diseases (NIAMS) encourage submission of investigator-initiated research grant applications to study restless legs syndrome (RLS) and periodic limb movement disorder. - The total amount to be awarded will depend on the number and type of applications received and on their scientific merit. Specific funds are not set-aside for this program. - The anticipated number of awards is not known. The number of individual awards will depend on the number and scientific merit of the applications received. - The type of mechanism to be used is the Research Project (R01) mechanism. - Eligible organizations include for-profit or non-profit domestic public or private institutions, units of state or local governments, eligible agencies of the Federal government, and foreign institutions. - Eligible principal investigators include any individual with the skills, knowledge and resources necessary to carry out the proposed research. - There is no limit on the number of different applications from an institution or individual.

The goal of this Request for Applications (RFA) is to solicit applications to identify specific genes and gene variants in localized chromosomal regions that confer susceptibility to autism. Fine mapping of disease loci, or quantitative trait loci (QTLs), is expected to occur in very large datasets of pre-existing samples that have high statistical power for fine mapping autism susceptibility loci. In order to improve the probability of obtaining biologically and clinically meaningful associations between genotypes and disease outcomes, this initiative will not be limited to fine-scale mapping of a disease locus but will proceed to the next level of positional identification of strong candidate genes via assessment of the functional significance of the autism - associated genetic variants. Such assessments should include approaches based on computational biology, comparative and evolutionary genomics, as well as experimental evidence from relevant in vitro or animal model studies designed to probe the effect of genetic variants on gene expression, splicing or function.Applications are encouraged to focus on complex modes of inheritance that include multiple risk factors, e.g., environmental, multigenic and epigenetic effects. New data collection activities will not be supported. Data - and biomaterials, if possible - analyzed in projects supported under this RFA can be included in a data management and cell repository facility maintained under the NIMH Human Genetics Initiative (http://nimhgenetics.org) and broadly distributed to the scientific community.

- The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD), the National Institute of Mental Health (NIMH), the International Rett Syndrome Association (IRSA) and the Rett Syndrome Research Foundation (RSRF) invite research grant applications aimed at understanding and/or treating Rett Syndrome (RTT). The recent demonstration that mutations in the MECP2 gene cause most cases of RTT has created new opportunities for both basic and clinical research. Included within the scope of this Program Announcement with set-aside funds (PAS) are developmental, neuroanatomical, molecular genetic, and pathophysiological research, therapy development projects and clinical studies. Studies of the role of MeCP2 in basic biological processes or in the etiology of other neurological or neurobehavioral disorders are also appropriate. - The participating organizations intend to commit a total of $2,600,000 to this PAS in addition to funds available for applications sent in response to this initiative that score within the paylines of the participating NIH Institutes. - Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. - This PAS will use the NIH R01, R21 and R03 mechanisms. - Eligible organizations include: for-profit or non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of State and local governments; eligible agencies of the Federal government; and domestic or foreign institutions/organizations. - Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. - There is no limit to the number of applications each applicant may submit. - The PHS 398 application materials are available at http://grants.nih.gov/grants/funding/phs398/phs398.html.

In 1999, at the direction of Congress, the National Institute on Aging (NIA), in conjunction with the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR) embarked on the Alzheimer's Disease (AD) Prevention Initiative. An important part of the AD Prevention Initiative is to quicken the pace for translating basic science findings into clinical trials to evaluate treatment and prevention strategies. This Program Announcement (PA) focuses on AD drug discovery while a companion PA is targeted to AD pilot clinical trials.

The NIH hereby notifies Principal Investigators holding specific types of NIH research grants (listed in the full announcement) that funds are available for administrative supplements to improve the diversity of the research workforce by supporting and recruiting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented. Although the administrative supplements supported under this program provide funding for less than one percent of all individuals involved in NIH supported research, the NIH has found these awards to be an effective means of encouraging institutions to recruit from currently underrepresented groups. Administrative supplements must support work within the scope of the original project.

-The purpose of this RFA is to enhance our understanding of the effects of Type 1 diabetes on the development of new blood vessels from preexisting vessels (angiogenesis), in order to open new therapeutic avenues to treat diabetic vasculopathies. This RFA seeks basic and clinical studies on the mechanisms of abnormal angiogenesis seen in the complications of diabetes in wound healing, nephropathy, neuropathy and peripheral, coronary and cerebral arterial diseases. -Applications are invited from multiple investigators conducting collaborative research projects that foster sharing of expertise between the angiogenesis and diabetes fields. -The participating institutes plan on contributing $3 million to fund 5-10 new R01 awards with project periods ranging from 2-4 years. -Non-profit or for-profit organizations are eligible, including public or private institutions and domestic and foreign institutions. -Investigators may submit more than one application as part of different collaborative groups. There should be no scientific or budgetary overlap. -The PHS 398 application can be obtained from http://grants.nih.gov/grants/funding/phs398/phs398.html -Telecommunications for the hearing impaired is available at: TTY 301-451-0088

This Program Announcement with set-aside funds (PAS) invites applications proposing clinical and translational research in multiple sclerosis (MS) and targeting the neurodegenerative aspect of this disease. It is not intended to solicit proposals in basic neuroscience or glial biology. Rather, applications responsive to this PAS will apply ideas, insights, and discoveries generated through basic scientific inquiry to the treatment of MS and will have an emphasis on activities directly focused on the development of neuroprotective and regenerative therapies for MS. Applications testing novel therapeutic interventions in animal models or in in vitro systems are encouraged as are applications for the development of technologies that would facilitate the monitoring of their efficacy. Clinical trials and interventions in MS patients are not covered by this PAS and applicants are directed to instead use the funding mechanisms and opportunities listed at http://www.ninds.nih.gov/funding/areas/clinical_trials/index.htm.

The National Institutes of Health (NIH) invite applications for specialized Centers to accelerate application of the latest advances in human stem cell biology for the development of novel diagnostic or therapeutic uses, and of preclinical studies employing human stem cells in animal models of disease. The P50 mechanism will be used to create three Centers of Excellence in Translational Human Stem Cell Research. These centers will bring together basic stem cell biologists, researchers and clinicians with disease-specific expertise, physicians and surgeons skilled in novel modes of cell delivery, and investigators experienced in developing and assessing animal models of human diseases to create new research teams, and to conduct hitherto-unexplored projects such as preclinical studies for cell-based therapy. This initiative targets critical gaps in research that are delaying the conversion of new discoveries to new therapies, and particularly encourages the formation of new, multidisciplinary teams involving scientists that may not have worked in the human stem cell field and those that incorporate the full spectrum of expertise and experience in translational medical research. We anticipate that such research will ultimately lead to innovative approaches for the prevention, treatment, and cure of disease, and accelerate the translation of basic scientific discoveries in the laboratory to new treatments for patients. The NIH intends to commit up to $4.5 million dollars in FY 2005 to fund three new Centers. Eligible organizations include domestic public or private institutions. There is no limit on the number of applications from an institution or individual. Any individual with the skills, knowledge and resources necessary to carry out the proposed research is invited to work with the institution to develop and application for support. Individuals from underrepresented or disadvantaged groups are always encouraged to apply for NIH programs. The PHS 398 application instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. For further assistance contact Grantsinfo, Telephone (301) 435-0714, Email: Grantsinfo@nih.gov.

On February 26, 2004, Executive Order 13329 (http://a257.g.akamaitech.net/7/257/2422/14mar20010800/edocket.access.gp… /2004/pdf/04-4436.pdf)was signed by President George W. Bush requiring SBIR/STTR agencies, to the extent permitted by law and in a manner consistent with the mission of the Department, to give high priority within the SBIR and STTR programs to manufacturing-related research and development (R&D). In response to this Executive Order, NIH, CDC, and the FDA are expanding their foci by encouraging biomedical research related to advanced processing, manufacturing processes, equipment and systems, and manufacturing workforce skills and protection.